PortalPublikationenBaseline characteristics and prevalence of HPV 6, 11, 16, 18...

Baseline characteristics and prevalence of HPV 6, 11, 16, 18 in young German women participating in phase III clinical trials of a quadrivalent HPV (6/11/16/18) vaccine.

Standard

Baseline characteristics and prevalence of HPV 6, 11, 16, 18 in young German women participating in phase III clinical trials of a quadrivalent HPV (6/11/16/18) vaccine. / Barthell, Elisabeth; Wölber, Linn; Hellner, Karin; Camerer, Birka; Gieseking, Friederike; Hauschild, Maik; Mylonas, Ioannis; Friese, Klaus; Sings, Heather; Railkar, Radha; Gause, Christine; Barr, Eliav.

in: ARCH GYNECOL OBSTET, 2008.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Barthell, E, Wölber, L, Hellner, K, Camerer, B, Gieseking, F, Hauschild, M, Mylonas, I, Friese, K, Sings, H, Railkar, R, Gause, C & Barr, E 2008, 'Baseline characteristics and prevalence of HPV 6, 11, 16, 18 in young German women participating in phase III clinical trials of a quadrivalent HPV (6/11/16/18) vaccine.', ARCH GYNECOL OBSTET. <http://www.ncbi.nlm.nih.gov/pubmed/18936950?dopt=Citation>

APA

Barthell, E., Wölber, L., Hellner, K., Camerer, B., Gieseking, F., Hauschild, M., Mylonas, I., Friese, K., Sings, H., Railkar, R., Gause, C., & Barr, E. (2008). Baseline characteristics and prevalence of HPV 6, 11, 16, 18 in young German women participating in phase III clinical trials of a quadrivalent HPV (6/11/16/18) vaccine. ARCH GYNECOL OBSTET. http://www.ncbi.nlm.nih.gov/pubmed/18936950?dopt=Citation

Vancouver

Barthell E, Wölber L, Hellner K, Camerer B, Gieseking F, Hauschild M et al. Baseline characteristics and prevalence of HPV 6, 11, 16, 18 in young German women participating in phase III clinical trials of a quadrivalent HPV (6/11/16/18) vaccine. ARCH GYNECOL OBSTET. 2008.

Bibtex

@article{323a5ff7e5c44ca883b18b8aa6d519b5,
title = "Baseline characteristics and prevalence of HPV 6, 11, 16, 18 in young German women participating in phase III clinical trials of a quadrivalent HPV (6/11/16/18) vaccine.",
abstract = "INTRODUCTION: As limited data among German women exist about HPV, Chlamydia trachomatis (CT) and Neisseria gonorrhoeae, we report the prevalence of these genital infections and general baseline demographics of the young German women enrolled in the phase III trials of the quadrivalent HPV vaccine. MATERIALS AND METHODS: German females (n = 437; 9-23 years) were recruited among 3 international phase 3 studies of an HPV-6/11/16/18 vaccine. We present baseline characteristics, prevalence of HPV-6/11/16/18 and, for women aged 16-23, abnormal cervical cytology and sexually transmitted diseases. RESULTS: Chlamydia trachomatis and Neisseria gonorrhoeae prevalence was 5 and 0.3%, respectively. Approximately 17% of participants had HPV-6, 11, 16, or 18 DNA or antibodies. All subjects",
author = "Elisabeth Barthell and Linn W{\"o}lber and Karin Hellner and Birka Camerer and Friederike Gieseking and Maik Hauschild and Ioannis Mylonas and Klaus Friese and Heather Sings and Radha Railkar and Christine Gause and Eliav Barr",
year = "2008",
language = "Deutsch",
journal = "ARCH GYNECOL OBSTET",
issn = "0932-0067",
publisher = "Springer",

}

RIS

TY - JOUR

T1 - Baseline characteristics and prevalence of HPV 6, 11, 16, 18 in young German women participating in phase III clinical trials of a quadrivalent HPV (6/11/16/18) vaccine.

AU - Barthell, Elisabeth

AU - Wölber, Linn

AU - Hellner, Karin

AU - Camerer, Birka

AU - Gieseking, Friederike

AU - Hauschild, Maik

AU - Mylonas, Ioannis

AU - Friese, Klaus

AU - Sings, Heather

AU - Railkar, Radha

AU - Gause, Christine

AU - Barr, Eliav

PY - 2008

Y1 - 2008

N2 - INTRODUCTION: As limited data among German women exist about HPV, Chlamydia trachomatis (CT) and Neisseria gonorrhoeae, we report the prevalence of these genital infections and general baseline demographics of the young German women enrolled in the phase III trials of the quadrivalent HPV vaccine. MATERIALS AND METHODS: German females (n = 437; 9-23 years) were recruited among 3 international phase 3 studies of an HPV-6/11/16/18 vaccine. We present baseline characteristics, prevalence of HPV-6/11/16/18 and, for women aged 16-23, abnormal cervical cytology and sexually transmitted diseases. RESULTS: Chlamydia trachomatis and Neisseria gonorrhoeae prevalence was 5 and 0.3%, respectively. Approximately 17% of participants had HPV-6, 11, 16, or 18 DNA or antibodies. All subjects

AB - INTRODUCTION: As limited data among German women exist about HPV, Chlamydia trachomatis (CT) and Neisseria gonorrhoeae, we report the prevalence of these genital infections and general baseline demographics of the young German women enrolled in the phase III trials of the quadrivalent HPV vaccine. MATERIALS AND METHODS: German females (n = 437; 9-23 years) were recruited among 3 international phase 3 studies of an HPV-6/11/16/18 vaccine. We present baseline characteristics, prevalence of HPV-6/11/16/18 and, for women aged 16-23, abnormal cervical cytology and sexually transmitted diseases. RESULTS: Chlamydia trachomatis and Neisseria gonorrhoeae prevalence was 5 and 0.3%, respectively. Approximately 17% of participants had HPV-6, 11, 16, or 18 DNA or antibodies. All subjects

M3 - SCORING: Zeitschriftenaufsatz

JO - ARCH GYNECOL OBSTET

JF - ARCH GYNECOL OBSTET

SN - 0932-0067

ER -